AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Research == Several forms of lipodystrophy cause insulin resistance, which has responded favorably to thiazolidinediones. There are some indications that thiazolidinediones provide some degree of protection against the initial stages of breast carcinoma development. Evidence was emerging in 2008 that vitamin E with thiazolidinediones is effective in the treatment of non-alcoholic steatohepatitis due to their combined antioxidant and insulin sensitizing effects, producing histological improvements in steatosis severity. Thiazolindinediones induce adipogenesis in subcutaneous fat deposits by activating PPARγ receptors. This effect has been used in transgender patients to shift body fat distribution towards a more gynoid pattern.
According to the Russian investigators, Yekaterina Kharebava noticed the movement of the Russian troops before the August 2008 War and reported this movement to the Georgian intelligence. In 2017, Russian president Vladimir Putin decreed to free another two women imprisoned for sending SMSes about the April 2008 Russian military deployment to Abkhazia. Kharebava and Sevastidi had already left the prison by that time.
Heart–lung machine (1951): Three UC faculty members developed the world's first functional heart–lung machine, making open-heart surgery possible. Fogarty heart catheter: A major advance in vascular surgery pioneered at UC during Dr. Thomas Fogarty's fellowship training. Benadryl (1942): Discovered by UC chemist George Rieveschl, Benadryl became the world's first antihistamine. Polio vaccine: Albert Sabin developed the first live, attenuated oral polio vaccine while working jointly at UC and Cincinnati Children's Hospital Medical Center, saving millions worldwide. Other significant contributions include definitive research on lead exposure in children, creation of one of the nation's first hematology–oncology divisions (1948), and establishment of pioneering laboratories in medical laser surgery (1961) and neurosurgical innovation (1980s).
==== Temperate surface bodies of water ==== A mesophilic start in surface bodies of waters hypothesis has evolved from Darwin's concept of a 'warm little pond' and the Oparin-Haldane hypothesis. Freshwater bodies under temperate climates can accumulate prebiotic materials while providing suitable environmental conditions conducive to simple life forms. The Archaean climate is uncertain. Atmospheric reconstructions from geochemical proxies and models suggest that sufficient greenhouse gases were present to maintain surface temperatures between 0–40 °C. If so, the temperature was suitable for life to begin. Evidence for mesophily from biomolecular studies includes Galtier's G+C nucleotide thermometer. G+C are more abundant in thermophiles due to the added stability of an additional hydrogen bond not present between A+T nucleotides. rRNA sequencing of modern lifeforms shows that LUCA's reconstructed G+C content was likely representative of moderate temperatures. The diversity of thermophiles today could be a product of convergent evolution and horizontal gene transfer rather than an inherited trait from LUCA. The reverse gyrase topoisomerase is found exclusively in thermophiles and hyperthermophiles, as it allows for coiling of DNA. This enzyme requires the complex molecule ATP to function. If an origin of life is hypothesised to involve a simple organism that had not yet evolved a membrane, let alone ATP, this would make the existence of reverse gyrase improbable.
== Symptoms and signs == Prolidase deficiency generally becomes evident during infancy, but initial symptoms can first manifest anytime from birth to young adulthood. The condition results in a very diverse set symptoms, the severity of which can vary significantly between patients, depending on the degree to which prolidase activity is hampered by the individual underlying mutation(s) in each case. It is even possible, though rare, for affected individuals to be asymptomatic, in which case the disorder can only be identified through laboratory screening of the prospective patient and/or their extended family. One of the signature features of PD is the elimination of high quantities of peptides through urine. In addition, most of those affected exhibit persistent skin lesions (starting from a mild rash) or ulcers, primarily on the legs and feet, the formation of which normally begins during childhood. Clinically, these, among other dermatological issues, represent the most distinguishing and most frequent symptoms. These may never recede, potentially leading to severe infections that can, in the worst case, necessitate amputation. PD patients exhibit a weak immune system and markedly elevated vulnerability to infections in general, and particularly those of the respiratory system, leading some who suffer from PD to acquire recurrent lung disease. They may also have an enlarged spleen (splenomegaly), and on some occasions the spleen and liver may both be enlarged (hepatosplenomegaly). Photosensitivity and hyperkeratosis have been associated with PD.
Sources: en.wikipedia.org
== Examples == ornithine translocase (SLC25A15), associated with ornithine translocase deficiency. carnitine-acylcarnitine translocase (SLC25A20), associated with carnitine-acylcarnitine translocase deficiency. Translocase of outer mitochondrial membrane 40 (TOMM40), a protein encoded by the TOMM40 gene, whose alleles differentially impact the risk for Alzheimer's disease
By decree of 8 December 1806, the territory was divided into districts and boroughs: Calabria retained the division of the two provinces of “Citeriore,” whose capital remained in Cosenza, and “Ulteriore,”” which had Monteleone assigned as its administrative seat, because of its relative ease of communication and military necessity. The provinces were presided over by an intendant and were divided into four districts, placed under the jurisdiction of their respective sub-districts, which in turn were divided into districts, each of which grouped a certain number of municipalities. In 1810 Joseph Bonaparte was replaced by Joachim Murat, Napoleon's brother-in-law (husband of Caroline Bonaparte). The new king accelerated social and economic modernization: he reformed the tax system, replacing the Bourbon tax levies such as the testatico, the focatico and the tassa d'industria, with a single direct land tax; from 1811 he initiated government inquiries to learn about the living conditions of rural populations, while showing an interest in mineral resources, as in the case of the mines connected to the Mongiana ironworks in the Serre. Napoleonic rule ended in 1815, after Napoleon's defeat at Waterloo. The deposed Bourbon ruler returnedto the throne, despite Murat's attempt to regain the throne with a small military expedition. The former king landed in Pizzo Calabro, but was betrayed and captured by Bourbon troops. He was sentenced to death by a military tribunal presided over by General Vito Nunziante and shot, on 13 October 1815, in the castle.
=== United Kingdom === In November 2023, Juniper was among several UK-registered online providers continuing to prescribe Ozempic for weight loss during a national shortage of semaglutide. The Advertising Standards Authority (ASA) issued an advice notice to Juniper over advertisements implying endorsement by National Health Service (NHS) workers. There were concerns about misleading claims and the promotion of prescription-onlu medicines. The ASA launched multiple investigations into online advertising by weight-loss providers, including Juniper. In June 2025, Juniper was among providers examined after test purchases showed weight-loss injections could be obtained following online questionnaires without real-time consultation. In September 2025, the growing private market for GLP-1 weight-loss medications in the UK had raised concerns about a two-tier system of access, with most users paying privately due to limited NHS availability. Juniper was offering private access to weight-loss treatments, while clinicians and public-health experts warned that cost barriers could exacerbate health inequalities and limit access for lower-income patients.
Dialkylbiaryl phosphine ligands are air-stable solids. Many are available commercially. They often can be synthesized in from inexpensive starting materials. One pot protocols have been conducted on >10 kilograms (22 lb) scales.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.